the cliff
Patent cliff
Drugs ranked by the soonest barrier to generic / biosimilar entry. Each row shows the earliest-expiring patent OR FDA exclusivity for that drug — whichever falls first determines when competitive pressure begins.
- May 29, 20358.6ypatentISOTRETINOINISOTRETINOINAmneal Pharmaceuticals of New York LLC
- Jun 26, 20358.7ypatentCyclophosphamidecyclophosphamide [INN]Long Grove Pharmaceuticals LLC
- Jul 9, 20358.7ypatentToprol-XLmetoprolol succinateMelinta Therapeutics LLC
- Oct 19, 20359.0ypatentVARENICLINE TARTRATEVARENICLINE TARTRATEOyster Point Pharma Inc
- Nov 6, 20359.0ypatentLisinoprillisinoprilCorePharma LLC
- Nov 13, 20359.0ypatentElixsure EXguaifenesinMoberg Pharma AB
- Dec 2, 20359.1ypatentArakodatafenoquine succinate$SXTP60 DEGREES PHARMACEUTICALS, INC.
- Jan 19, 20369.2ypatentTascenso ODTfingolimod [INN]Cycle Pharmaceuticals Ltd
- Feb 12, 20369.3ypatentRosuvastatin Calciumrosuvastatin calciumTeva Pharmaceuticals USA Inc
- Feb 16, 20369.3ypatentGvokeglucagon [INN]$XERSXeris Biopharma Holdings, Inc.
- Apr 21, 20369.5ypatentLansoprazolelansoprazoleNATCO Pharma Inc.
- Oct 11, 203610.0ypatentPROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDEDEXTROMETHORPHAN HYDROBROMIDEHetero Labs Ltd
- Oct 28, 203610.0ypatentCarospirspironolactone [INN]CMP Pharma Inc
sourced from FDA Orange Book · approved drugs only · biologics + biosimilars excluded (those live in the Purple Book — coming soon)